Plain-English translation of NCT05597345 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to treat smoldering multiple myeloma, an early stage of a blood cancer where abnormal plasma cells are growing in the bone marrow but haven't yet caused serious symptoms. works by blocking a protein that helps cancer cells survive and divide. The study will see if giving this medication to people at high risk of progression can prevent or delay the disease from becoming more severe.
Right now, doctors typically just watch patients with smoldering multiple myeloma closely without treating them, because older studies didn't show that early treatment helped. However, newer research suggests that treating patients at highest risk of getting sicker might actually prevent or delay that progression—and this trial aims to find out if this medication is an effective way to do that.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as a tablet taken by mouth once per week for up to 12 cycles, with each cycle lasting 28 days (about 12 months total). You would need lab work within 28 days before starting to confirm you're healthy enough for the study, and you would likely have regular check-ins with the research team to monitor how you're doing and watch for any side effects. Because this medication can affect pregnancy, you would also need to use effective birth control throughout the study and for 6 months after it ends if you have reproductive potential.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States